JAGX Jaguar Health Inc
Price (delayed)
$4.67
Market cap
$3.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$130.69
Enterprise value
$31.67M
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating
Highlights
Jaguar Health's gross profit has increased by 26% YoY and by 16% QoQ
The company's revenue rose by 20% YoY and by 12% QoQ
The EPS has shrunk by 131% QoQ but it has soared by 95% YoY
The equity rose by 47% YoY but it fell by 46% QoQ
JAGX's quick ratio is down by 33% since the previous quarter and by 21% year-on-year
JAGX's debt is up by 7% since the previous quarter
Key stats
What are the main financial stats of JAGX
Market
Valuations
Earnings
Shares outstanding
674,043
Market cap
$3.15M
Enterprise value
$31.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
0.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
Revenue
$11.69M
Gross profit
$9.73M
Operating income
-$30.83M
Net income
-$38.49M
EBIT
-$38.26M
EBITDA
-$35.9M
Free cash flow
-$29.4M
Per share
Balance sheet
Liquidity
EPS
-$130.69
EPS diluted
-$130.69
Free cash flow per share
-$99.82
Book value per share
$15.44
Revenue per share
$39.69
TBVPS
$118.65
Total assets
$53.43M
Total liabilities
$44.45M
Debt
$36.53M
Equity
$7.29M
Working capital
$12.49M
Debt to equity
5.01
Current ratio
1.63
Quick ratio
0.49
Net debt/EBITDA
-0.79
Margins
Efficiency
Dividend
EBITDA margin
-307.2%
Gross margin
83.3%
Net margin
-329.3%
Operating margin
-263.8%
Return on assets
-67.3%
Return on equity
-309.2%
Return on invested capital
-92.7%
Return on capital employed
-113.5%
Return on sales
-327.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAGX stock price
How has the Jaguar Health stock price performed over time
Intraday
-1.89%
1 week
-8.97%
1 month
-69.71%
1 year
-95.79%
YTD
-81.5%
QTD
-1.89%
Financial performance
How have Jaguar Health's revenue and profit performed over time
Revenue
$11.69M
Gross profit
$9.73M
Operating income
-$30.83M
Net income
-$38.49M
Gross margin
83.3%
Net margin
-329.3%
Jaguar Health's gross profit has increased by 26% YoY and by 16% QoQ
JAGX's operating margin is up by 25% YoY and by 9% from the previous quarter
JAGX's net margin is up by 22% year-on-year and by 9% since the previous quarter
The company's revenue rose by 20% YoY and by 12% QoQ
Growth
What is Jaguar Health's growth rate over time
Valuation
What is Jaguar Health stock price valuation
P/E
N/A
P/B
0.3
P/S
0.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
The EPS has shrunk by 131% QoQ but it has soared by 95% YoY
The price to book (P/B) is 93% lower than the 5-year quarterly average of 4.6 and 69% lower than the last 4 quarters average of 1.0
The equity rose by 47% YoY but it fell by 46% QoQ
The price to sales (P/S) is 98% lower than the 5-year quarterly average of 5.9 and 88% lower than the last 4 quarters average of 1.0
The company's revenue rose by 20% YoY and by 12% QoQ
Efficiency
How efficient is Jaguar Health business performance
The ROE has soared by 64% YoY and by 2.8% QoQ
The company's return on assets rose by 16% YoY
The ROS rose by 8% YoY and by 8% QoQ
The return on invested capital has increased by 7% year-on-year but it has declined by 5% since the previous quarter
Dividends
What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAGX.
Financial health
How did Jaguar Health financials performed over time
JAGX's total assets is 20% greater than its total liabilities
JAGX's quick ratio is down by 33% since the previous quarter and by 21% year-on-year
Jaguar Health's current ratio has decreased by 19% YoY and by 11% from the previous quarter
The debt to equity has soared by 99% from the previous quarter but it has contracted by 33% YoY
The equity rose by 47% YoY but it fell by 46% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.